Popular Articles

BioPartners GmbH Withdraws Its Application For Biferonex (interferon Beta-1a)
The European Medicines Agency has been formally notified by BioPartners GmbH of its decision to withdraw its application for Biferonex (interferon beta-1a), 6 million-international-unit solution for injection, prefilled syringes for subcutaneous administration.
pharmacy online
Pilot Study Confirms That Children With Autism Need To Be Taught In Smaller Groups
Since the 1970s, there has been much debate surrounding the fact that individuals with autism have difficulty in understanding speech in situations where there is background speech or noise.
News of the day
Swedish University President Awarded Prestigious Distinction
Karolinska Institutet accounts for almost half of the academic medical research conducted in Sweden, and contributes regularly to new discoveries that save lives and alleviate suffering. Today, the university"s president, Harriet Wallberg-Henriksson, is to receive an honorary distinction for eminent women in science by Exploratorium, the renowned American science museum.
Diagnostics

Merck Seeks European License For Cladribine for relapsing remitting MS

Merck Serono announced that it is seeking a European license for cladribine, its oral therapy that is in late-stage clinical trials for relapsing remitting MS. The announcement comes after results of a phase III clinical trial were reported in April at the annual American Academy of Neurology meeting in Seattle Washington. If the application meets all of the regulatory hurdles, it is set to be the first oral disease modifying drug available to people with MS. If no delays are made, cladribine could be available as early as the middle of 2010, which could mean more choice for people with MS. Multiple Scleroris Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):